Professor Raven Kok
Associate Professor
Department of Microbiology, The University of Hong Kong
biography
Professor Kok is currently an Associate Professor in the Department of Microbiology and Assistant Dean of the Faculty of Medicine at The University of Hong Kong. He is a molecular virologist and has been interested in host-virus interactions and host antiviral responses, including “interferon signaling”. He first identified a host antiviral protein, PACT, that recognizes viral defective interfering RNAs and optimally induces type-I interferon production, an indispensable primary antiviral response during early infection. Beyond basic molecular virology, Professor Kok and his team established several novel vaccine platforms and developed innate immunity-driven vaccines such as an intradermal influenza vaccine, a single-round live pan-Sarbecovirus vaccine, and RNA-scaffold protein mucosal vaccines.
Title
RNA scaffold of an inhalable protein vaccine functions as a novel mucosal vaccine adjuvant
abstract
Effective mucosal vaccination with recombinant proteins requires adjuvants that enhance local immunity without inducing excessive inflammation. Here, we identify the RNA scaffold of an inhalable protein vaccine as a multifunctional mucosal adjuvant that integrates antigen assembly with immune stimulation. Within the RNA-Scaffold-Protein Vaccine (RSPVac), single-stranded RNA associates with a nucleoprotein adaptor to organize protein antigens into a self-adjuvanted ribonucleoprotein complex. Intranasal immunization elicited robust mucosal IgA, systemic antibody responses, and antigen-specific mucosal T cells in preclinical models. Early immune profiling revealed strong but transient cytokine expression and recruitment of regulatory and effector neutrophil subsets, consistent with controlled mucosal activation. Vaccination protected against matched respiratory virus challenges, while protection against unmatched influenza viruses was associated with trained immune cell profiles. Impaired responses to mutant RSPVac further suggest that vaccine activity depends on coordinated structural and immunostimulatory properties. Together, these findings support the RNA scaffold as a promising mucosal adjuvant within a modular, non-infectious protein vaccine platform for respiratory virus prevention.
